A Singaporean pharmaceutical company has developed a new oral drug for Alzheimer’s disease. The results of its phase III clinical trial are positive, which can slow the decline of cognitive function and brain atrophy in patients. Therapeutic drugs, including Taiwanese Xufu factory (4119-TW) is the exclusive raw material supplier of this new drug, which will help Xu Fu accelerate its growth and eliminate the decline of recent years.
Xu Fu said that a customer who develops a new drug for Alzheimer’s disease should apply for a drug license next year, and his factories will also be inspected and certified at the same time. As the customer is very optimistic about sales, he expects to accelerate the company’s operations to return to pre-disaster levels.
According to the results of phase III clinical trials of new oral Alzheimer’s drugs announced by TauRx Pharmaceuticals, a Singaporean pharmaceutical company, after the first patients received drug treatment, their cognition and brain atrophy they kept getting better; compared with patients who had not used drugs in the past, mild to moderate patients treated with drugs had more stable cognitive function and reduced brain atrophy.
With positive results from clinical trials of new drugs, the company recently raised $119 million and will apply for drug licensing from regulatory authorities in the United States, Canada and the United Kingdom, and present the research results to the Alzheimer’s Disease Center in San Francisco, USA, which will debut at the Conference on Clinical Trials in Disease (CTAD) later this month.
Xu Fu expects that the production capacity will gradually recover after clearing the fire haze. With the continued shipment of existing product lines, the operation will return to the pre-disaster level in the second half of next year. In the future, it will be produced in new plant in Guanyin, which will lead to a significant increase in revenues.
Alzheimer’s disease is a neurodegenerative brain disease and a type of dementia. The development of the disease is irreversible and does not cause direct death. Most patients die from other complications. According to statistics, there are about 35 million Alzheimer’s patients in the world, of which more than 6 million in the United States. In 2050, there will be 13 million people, and the business opportunity for drug treatment will reach $300 billion. Americans.
In fact, the advent of new drugs for Alzheimer’s disease in the United States dates back to 2003. At that time, the annual sales of the two approved drugs was about 1.5 billion US dollars, but the new drug could only relieve the symptoms caused by Alzheimer’s disease, can not slow down the disease, so many international pharmaceutical companies have invested in the development in recent years, including the joint development of Japan Weicai and Biogen of the United States, Roche Pharmaceuticals, etc.
